Intranasal Zavegepant is Effective and Well Tolerated for the Acute Treatment of Migraine: A Phase 2/3 Dose-Ranging Clinical trial (4976)
Robert Croop, Jennifer Madonia, Charles M. Conway, Alexandra Thiry, Micaela Forshaw, Abigail Murphy, Christopher Jensen, Gene M. Dubowchik, Vlad Coric, Richard B. Lipton
Abstract
Evaluate the efficacy, safety, and tolerability of intranasal zavegepant in the acute treatment of migraine.
Topics & Concepts
MigraineMedicineDose-ranging studyClinical trialPhases of clinical researchNasal administrationMigraine DisordersAnesthesiaInternal medicinePharmacologyAlternative medicineDouble blindPathologyPlaceboMigraine and Headache StudiesBotulinum Toxin and Related Neurological DisordersAttention Deficit Hyperactivity Disorder